Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab plus cyclophosphamide, doxoru...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Tilly, Hervé, Rai, Shinya, Zhang, Huilai, Jin, Jie, Goto, Hideki, Terui, Yasuhito, Shin, Ho-Jin, Kim, Won Seog, Cao, Junning, Feng, Jifeng, Eom, Hyeon Seok, Kim, Tae Min, Tsai, Xavier Cheng-Hong, Gau, Jyh-Pyng, Koh, Hideo, Zhang, Liling, Song, Yongping, Yang, Yu, Li, Wei, Huang, He, Ando, Kiyoshi, Sharman, Jeff P., Sehn, Laurie H., Bu, Lilian, Wang, Xin, Jiang, Yanwen, Hirata, Jamie, Lee, Calvin, Zhu, Jun, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646777/
https://www.ncbi.nlm.nih.gov/pubmed/36626583
http://dx.doi.org/10.1182/blood.2022017734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646777/
https://www.ncbi.nlm.nih.gov/pubmed/36626583
http://dx.doi.org/10.1182/blood.2022017734

Ejemplares similares